Zobrazeno 1 - 10
of 85
pro vyhledávání: '"U, Brennscheidt"'
Publikováno v:
The Journal of Clinical Pharmacology. 41:79-84
The aim of the present study was to investigate the pharmacokinetics of tilidine and its metabolites during the dialysis procedure and in the dialysis-free interval. Tilidine is a prodrug that is metabolized presystemically into the active metabolite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5659bc35a7ef713aff41a784c33317cd
https://doi.org/10.1177/00912700122009863
https://doi.org/10.1177/00912700122009863
Publikováno v:
European Journal of Cancer. 33:1050-1054
High-dose interleukin-2 (IL-2) treatment has demonstrated promising antitumour activity in renal cell carcinoma (RCC) and malignant melanoma (MM) and has been shown to induce broad immunological effects. The optimal IL-2 dose and schedule, however, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5446a1f199db0493c374c6cdeada114
https://doi.org/10.1016/s0959-8049(96)00530-8
https://doi.org/10.1016/s0959-8049(96)00530-8
Autor:
Felicia M. Rosenthal, Andreas Mackensen, Albrecht Lindemann, J. Hasse, Gabriele Köhler, B Franke, W Schultze-Seemann, Hendrik Veelken, U Brennscheidt, D Becker, Peter Kulmburg, M Lahn, H Keller, E.H. Farthmann, Roland Mertelsmann
Publikováno v:
International Journal of Cancer. 70:269-277
Tumor cells transfected to express immunostimulatory cytokines, or admixed with similarly modified bystander cells, are able to induce immune responses against unmodified tumor cells in animal models. For treatment of human patients, a vaccine compos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4494e0ea9f0208d900c565dd3175dbc
https://doi.org/10.1002/(sici)1097-0215(19970127)70:3<269::aid-ijc4>3.0.co
https://doi.org/10.1002/(sici)1097-0215(19970127)70:3<269::aid-ijc4>3.0.co
Autor:
H U Grimme, I. Tamm, R H Mertelsmann, E. Schopf, Albrecht Lindemann, U. Brennscheidt, E. Bergen, J. C. Simon
Publikováno v:
Oncology. 54:270-274
Based on encouraging reports of improved response rates with the use of dacarbazine (DTIC) in combination with recombinant interferon alpha-2a (rIFN-alpha-2a) in patients with metastatic malignant melanoma, we conducted a phase II study to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75957b3effd8d21868c2b1e5d2cc1775
https://doi.org/10.1159/000227701
https://doi.org/10.1159/000227701
Publikováno v:
European Journal of Immunology. 23:3146-3150
The product of the c-raf-1 proto-oncogene, Raf-1, is known to encode a 74-kDa ubiquitously expressed cytoplasmic serine/threonine kinase. Various growth factors such as epidermal growth factor, acidic fibroblast growth factor, platelet-derived growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be641a2bc69c7ee90edb1919bd5907f3
https://doi.org/10.1002/eji.1830231216
https://doi.org/10.1002/eji.1830231216
Autor:
Stephen Clarke, U. Brennscheidt, J.-P. Delord, Ashok Rakhit, Scott Fettner, P. Beale, E. Van Cutsem, Roland Bugat, Chris Verslype, A. Feyereislova
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(2)
Background Dysregulation of the epidermal growth factor receptor (HER1/EGFR) has been reported in colorectal cancer (CRC). Erlotinib is a potent inhibitor of HER1/EGFR-mediated signaling. This trial of patients with metastatic CRC (MCRC) examined the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::255ab0b85d24f339a5981ebabdac608e
https://pubmed.ncbi.nlm.nih.gov/17986625
https://pubmed.ncbi.nlm.nih.gov/17986625
Autor:
Max L. Birnstiel, H. A. Weber, A. Schneeberger, Hendrik Veelken, Jiri Trcka, Thor Voigt, Georg Stingl, E.-R. Kempe, Kurt Zatloukal, Klaus Wolff, U. Brennscheidt, Eva-B. Bröcker, Ernst Wagner, Susanne Schreiber, Roland Mertelsmann, Eckhart Kämpgen, Michael Buschle, G. Maass
Publikováno v:
Journal of Molecular Medicine. 75:297-299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fce3827668d568c6aa1640665b372cd6
https://doi.org/10.1007/s001090050115
https://doi.org/10.1007/s001090050115
Autor:
U. Brennscheidt, Albrecht Lindemann
Publikováno v:
European Journal of Cancer. 30:412-414
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29751e63698d75946a60ea3f5a19c765
https://doi.org/10.1016/0959-8049(94)90268-2
https://doi.org/10.1016/0959-8049(94)90268-2
Publikováno v:
Alimentary pharmacologytherapeutics. 11(5)
Aim: To investigate the effects of intravenous pentazocine and tilidine on sphincter of Oddi motility. Methods: Twenty patients with suspected sphincter of Oddi dysfunction were enrolled in a prospective, double-blind study. Sphincter of Oddi motilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f7512980315b08bd5a04a6f009c9731
https://pubmed.ncbi.nlm.nih.gov/9354211
https://pubmed.ncbi.nlm.nih.gov/9354211
Autor:
Peter Kulmburg, Andreas Mackensen, Michael Lahn, Albrecht Lindemann, Gabriele Köhler, U. Brennscheidt, Brigitte Franke, Felicia Dr Rosenthal, Daniel Becker, Sebastian Wittnebel, Roland Mertelsmann, Hendrik Veelken
Publikováno v:
Journal of molecular medicine (Berlin, Germany). 75(4)
In a phase I trial designed to study a vaccine composed of autologous tumor cells and interleukin-2 gene transfected fibroblasts we analyzed lymphocytes infiltrating the vaccination site (VIL) in two melanoma patients. Functional studies demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d80091b5d5f492fadb6e878adea04b
https://pubmed.ncbi.nlm.nih.gov/9151215
https://pubmed.ncbi.nlm.nih.gov/9151215